Document is current

Article History

Received: 2 October 2025

Revised: 4 February 2026

Accepted: 5 February 2026

First Online: 20 February 2026

Declarations

:

: Katsuto Takenaka reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., Takeda Pharmaceutical, MSD, and GlaxoSmithKlineK.K. Tomoki Ito reports research funds under contract from Asahi Kasei Pharma and Meiji Seika Pharma; and honoraria from Novartis Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Janssen Pharmaceutical, Bristol‐Myers Squibb, AbbVie G.K.., AstraZeneca K.K., Argenx Japan K.K., and BeOne Medicine. Norio Komatsu reports research funds under contract from PharmaEssentia Japan K.K.; and a board member of PharmaEssentia Japan K.K. Hiroki Yamaguchi reports honoraria from Nippon Shinyaku Pharmaceutical, PharmaEssentia Japan K.K., Novartis Pharmaceutical, Daiichi Sankyo, AbbVie G.K., Astellas Pharma, Chugai Pharmaceutical, Genmab A/S, Sanofi K.K., Janssen Pharmaceutical, Kyowa Kirin, Alexion Pharma G.K., AstraZeneca K.K., Shionogi, and Ono Pharmaceutical; and consulting fees from Nippon Shinyaku Pharmaceutical, PharmaEssentia Japan K.K., Novartis Pharmaceutical, AbbVie G.K., Sumitomo Pharma, and Ono Pharmaceutical. Keita Kirito reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K. Akihiro Tomita reports honoraria from AstraZeneca K.K., Chugai Pharmaceutical, AbbVie G.K., Takeda Pharmaceutical, Nippon Zenyaku Kogyo, SymBio Pharmaceutical, Kyowa Kirin, Genmab A/S, Eisai, Astellas Pharma, Janssen Pharmaceutical, and Bristol‐Myers Squibb. Yuka Sugimoto reports research funds under contract from Toyo Kohan, Incyte Biosciences Japan G.K., MSD, Sumitomo Pharma, and Sobi Japan; and honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K.; and serving on the editorial board of Japan Society of Hematology. Hideho Wada reports honoraria from Recordati Rare Diseases Japan K.K., Sanofi K.K., and Gilead Sciences. Akihiko Gotoh reports research funds under contract from Asahi Kasei Pharma, Taiho Pharmaceutical, Otsuka Pharmaceutical, Kyowa Kirin, and Chugai Pharmaceutical; and honoraria from PharmaEssentia Japan K.K., Novartis Pharma, Alexion Pharmaceuticals, Asahi Kasei Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Shinyaku Pharmaceutical, Chugai Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, Daiichi Sankyo, GlaxoSmithKline K.K., Kyowa Kirin, Janssen Pharmaceutical K.K., Pfizer Japan, and Sanofi K.K.; consulting fees from PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals; and serving on advisory board for PharmaEssentia Japan K.K., Chugai Pharmaceutical, and Alexion Pharmaceuticals. Kazuhiko Ikeda reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K., and Takeda Pharmaceutical. Toshinori Kondo reports honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., GlaxoSmithKline K.K., Nippon Shinyaku Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical, and Bristol‐Myers Squibb. Yasushi Miyazaki reports honoraria from Novartis Pharmaceutical, Chugai Pharmaceutical, Bristol‐Myers Squibb, Daiichi Sankyo, AbbVie G.K., and Incyte Biosciences Japan G.K.; and serving as managing director of Japan Adult Leukemia Study Group; and serving on the editorial board of Japan Society of Hematology. Kazuya Shimoda reports research funds under contract from Incyte Biosciences Japan G.K., Sumitomo Pharma, and PharmaEssentia Japan K.K.; and honoraria from Novartis Pharmaceutical, PharmaEssentia Japan K.K., and GlaxoSmithKline K.K.; and serving on advisory board for GlaxoSmithKline K.K.,　Sumitomo Pharma, and Merck. Hitoshi Kiyoi reports research funds under contract from FUJIFILM. Otsuka Pharmaceutical, Kyowa Kirin, Perseus Proteomics, Bristol-Myers Squibb, Daiichi Sankyo, AbbVie G.K., Astellas Pharma, CURED, Chugai Pharmaceutical, Nippon Zenyaku Kogyo, Eisai, Nippon Shinyaku Pharmaceutical, Takeda Pharmaceutical, and Sumitomo Pharma; and honoraria from Astellas Pharma, AbbVie G.K., and Chugai Pharmaceutical. Koichi Akashi reports research funds under contract from AbbVie G.K. and Kyowa Kirin; and honoraria from AbbVie G.K., Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin, Janssen Pharmaceutical, Nippon Shinyaku Pharmaceutical, and Asahi Kasei Pharma. Itaru Matsumura reports research funds under contract from Chugai Pharmaceutical, Asahi Kasei Pharma, Kyowa Kirin, Sumitomo Pharma, Eisai, Taiho Pharmaceutical, AbbVie G.K., and Otsuka Pharmaceutical; and honoraria from Novartis Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Janssen Pharmaceutical, Pfizer Japan, Otsuka Pharmaceutical, AbbVie G.K., Takeda Pharmaceutical, Ono Pharmaceutical. SymBio Pharmaceutical, Sanofi K.K., Astellas Pharma, and AstraZeneca K.K.; and consulting fee from Otsuka Pharmaceutical. Akifumi Takaori reports research funds under contract from PharmaEssentia Japan K.K.; and honoraria from Novartis Pharmaceutical and Janssen Pharmaceutical; and serving on the editorial board of Japan Society of Hematology. None of the other authors have any conflicts of interest to declare.